ATE260678T1 - Verfahren zur detektion von endometriosis - Google Patents

Verfahren zur detektion von endometriosis

Info

Publication number
ATE260678T1
ATE260678T1 AT00919954T AT00919954T ATE260678T1 AT E260678 T1 ATE260678 T1 AT E260678T1 AT 00919954 T AT00919954 T AT 00919954T AT 00919954 T AT00919954 T AT 00919954T AT E260678 T1 ATE260678 T1 AT E260678T1
Authority
AT
Austria
Prior art keywords
detecting
eosinophil peroxidase
component
treating endometriosis
targeting molecules
Prior art date
Application number
AT00919954T
Other languages
English (en)
Inventor
Rosalyn D Blumenthal
David M Goldenberg
Michael Samoszuk
Original Assignee
Ct Molecular Med & Immunology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Molecular Med & Immunology filed Critical Ct Molecular Med & Immunology
Application granted granted Critical
Publication of ATE260678T1 publication Critical patent/ATE260678T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1075Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/36Gynecology or obstetrics
    • G01N2800/364Endometriosis, i.e. non-malignant disorder in which functioning endometrial tissue is present outside the uterine cavity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
AT00919954T 1999-04-02 2000-03-31 Verfahren zur detektion von endometriosis ATE260678T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12747799P 1999-04-02 1999-04-02
PCT/US2000/008581 WO2000059547A2 (en) 1999-04-02 2000-03-31 Method of detecting endometriosis

Publications (1)

Publication Number Publication Date
ATE260678T1 true ATE260678T1 (de) 2004-03-15

Family

ID=22430337

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00919954T ATE260678T1 (de) 1999-04-02 2000-03-31 Verfahren zur detektion von endometriosis

Country Status (8)

Country Link
US (1) US6540980B1 (de)
EP (1) EP1169064B1 (de)
JP (1) JP2002541124A (de)
AT (1) ATE260678T1 (de)
AU (1) AU4056000A (de)
CA (1) CA2366774A1 (de)
DE (1) DE60008712D1 (de)
WO (1) WO2000059547A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962702B2 (en) * 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
US7138103B2 (en) * 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US7833528B2 (en) * 1998-06-22 2010-11-16 Immunomedics, Inc. Use of multispecific, non-covalent complexes for targeted delivery of therapeutics
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
US7897140B2 (en) * 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
AU2003248747A1 (en) 2002-06-27 2004-01-19 Health Research, Inc. Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy
WO2004005289A2 (en) * 2002-07-02 2004-01-15 Health Research, Inc. Efficient synthesis of pyropheophorbide a and its derivatives
EP1603535A4 (de) * 2003-03-18 2008-10-15 Ethicon Inc Aromatase-hemmer-diagnose und therapie
US20050155097A1 (en) * 2004-01-12 2005-07-14 Lee James J. Eosinophil-deficient transgenic animals
US20060008876A1 (en) * 2004-07-07 2006-01-12 Shami A S E ME-5, ME-2, and EPP2: human protein antigens reactive with autoantibodies present in the serum of women suffering from endometriosis
JP4954709B2 (ja) * 2004-10-28 2012-06-20 協和発酵キリン株式会社 子宮内膜症治療剤
WO2007076501A2 (en) * 2005-12-23 2007-07-05 The Burnham Institute For Medical Research Endometriosis cell targeting peptide and uses thereof
US20080306034A1 (en) * 2007-06-11 2008-12-11 Juneau Biosciences, Llc Method of Administering a Therapeutic
US8932993B1 (en) 2007-06-11 2015-01-13 Juneau Biosciences, LLC. Method of testing for endometriosis and treatment therefor
US11287425B2 (en) * 2009-04-22 2022-03-29 Juneau Biosciences, Llc Genetic markers associated with endometriosis and use thereof
US20080305967A1 (en) * 2007-06-11 2008-12-11 Juneau Biosciences, Llc Genetic Markers Associated with Endometriosis and Use Thereof
US20130171062A1 (en) * 2010-04-05 2013-07-04 University Of Utah Research Foundation Mapping in vivo eosinophil activation in eosinophilic esophagitis
KR20140102294A (ko) 2011-12-13 2014-08-21 엔진아이씨 몰레큘러 딜리버리 피티와이 리미티드 뇌 종양에 대한 치료제의 전달을 위한 박테리아 유래된, 무손상 미니세포
DE102012002929A1 (de) 2012-02-14 2013-08-14 Jürgen Lewald Minimalinvasives Verfahren für die Diagnose und die Therapieverlaufskontrolle der Endometriose
US9434991B2 (en) 2013-03-07 2016-09-06 Juneau Biosciences, LLC. Method of testing for endometriosis and treatment therefor
GB202202919D0 (en) 2022-03-02 2022-04-13 Serac Healthcare Ltd Methods for imaging integrin expression

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4782840A (en) * 1984-03-02 1988-11-08 Neoprobe Corporation Method for locating, differentiating, and removing neoplasms
US4932412A (en) * 1986-12-18 1990-06-12 Immunomedics, Inc. Intraoperative and endoscopic tumor detection and therapy
US5478725A (en) * 1992-06-12 1995-12-26 University Of Pennsylvania αv β3 integrin as a predictor of endometriosis
US5843673A (en) * 1994-10-25 1998-12-01 Curators Of The University Of Missouri Method of screening for endometriosis
US5831035A (en) * 1994-10-25 1998-11-03 Curators Of The University Of Missouri Antibody against human endometrial stromal cell glycoprotein
US5567828A (en) * 1995-06-07 1996-10-22 Eli Lilly And Company Compounds and compositions with nitrogen-containing non-basic side
CA2214196A1 (en) * 1996-09-26 1998-03-26 Eli Lilly And Company Benzo[b]indeno[2,1-d]thiophene compounds, intermediates, processes, compositions and methods

Also Published As

Publication number Publication date
JP2002541124A (ja) 2002-12-03
WO2000059547A2 (en) 2000-10-12
EP1169064A2 (de) 2002-01-09
DE60008712D1 (de) 2004-04-08
AU4056000A (en) 2000-10-23
US6540980B1 (en) 2003-04-01
CA2366774A1 (en) 2000-10-12
WO2000059547A3 (en) 2001-07-26
EP1169064B1 (de) 2004-03-03

Similar Documents

Publication Publication Date Title
DE60008712D1 (de) Verfahren zur detektion von endometriosis
DE69914138D1 (de) System, gerät und verfahren zur positionsbestimmung von meerestieren
DE60220251D1 (de) Nadelfreie injektionsvorrichtung für den einmaligen gebrauch und verfahren dafür
DE10085390T1 (de) Verfahren und Vorrichtung zur Adressuche längster Übereinstimmung
DE60022304D1 (de) Verfahren und Anordnung zur Ortung von Sprechern
ATE520466T1 (de) Apparat und verfahren zur modifizierung von magnetisch inmmobilizierte biomolekulen
MXPA02001697A (es) Aparato y metodo para localizar la fuente de una senal desconocida.
PT1214936E (pt) Utilizacao de derivados de tiazolidina ou pirrolidina de aminoacidos como agentes anti-hiperglicemicos
DE60106854D1 (de) Verfahren und Vorrichtung zur Elektroentionisierung von Wasser
DE60026767D1 (de) System und Verfahren zum Lernen von Benutzerpräferenzen
ATE277671T1 (de) Vorrichtung zur verbesserung der transdermalen abnahme von körperflüssigkeiten
DE69732152D1 (de) Vorrichtung zur Behandlung von Kopfschmerzen
DE60208278D1 (de) System und Verfahren zum Testen von Nukleinsäuremolekülen
DE60025368D1 (de) Verfahren zum identifizieren von prostaglandin d2 rezeptor modulatoren
DE69838689D1 (de) Verfahren zur Aktualisierung von Konten
DE69904525D1 (de) Verfahren zur Generierung von Pseudo-Zufallszahlen
DE60141965D1 (de) Verfahren und vorrichtung für artilleriegeschosse
DE60038478D1 (de) Vorrichtung zur Injektion von Kontrastmitteln
DE69826797D1 (de) Verfahren zur Generierung von Korrekturtabellen zur Detektion von Fehlzündungen mittels neuronaler Netzwerke
DE60025692D1 (de) Verfahren und Vorrichtung zur Weiterleitung von Verbindungszustandsinformationen mittels Mehrfachsendung
DE60020050D1 (de) Verfahren und Vorrichtung zur Ortung der Quelle von Teilentladungen
DE59913841D1 (de) EEPROM und Verfahren zur Ansteuerung eines EEPROM
ATE397098T1 (de) Verfahren zur diagnostik von eierstock endometriose
DE60030811D1 (de) Verfahren zur Ampifizierung von RNA
DE60206447D1 (de) Verfahren und Vorrichtung zum Ausbalancieren von Superkapazitäten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties